Loading clinical trials...

Indomethacin PK-PD in Extremely Preterm Neonates | Clinical Trials | Clareo Health

WITHDRAWNPhase 2NCT04025177

Indomethacin PK-PD in Extremely Preterm Neonates

This is a phase II open-label study evaluating the pharmacokinetics and pharmacodynamics of targeted early use of indomethacin for PDA treatment in preterm neonates \<27 weeks' gestational age.

Lead sponsor: University of Manitoba•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Related studies

Active Not RecruitingPhase 3

Management of the PDA Trial

NCT03456336 · Infant, Premature, Patent Ductus Arteriosus, and more

COMPLETEDPhase 2/3

Prophylactic IV Paracetamol in Extremely Premature Infants

NCT07067177 · Patent Ductus Arteriosus in Preterm Infants, Patent Ductus Arteriosus After Premature Birth, and more

UNKNOWN

Hemodynamically Important Patent Ductus Arteriosus in Newborns Under 32 Weeks

NCT05686343 · Patent Ductus Arteriosus After Premature Birth

UNKNOWN

Combined Lung Ultrasounds and Transthoracic Electrical Bioimpedance in Preterm Infants With Respiratory Distress.

NCT04359134 · Respiratory Distress Syndrome in Premature Infant, Patent Ductus Arteriosus After Premature Birth, and more

UNKNOWNNA

The Effects of Phototherapy in Preterm Infants Pda

NCT03675425 · Patent Ductus Arteriosus After Premature Birth, Hyper Bilirubinemia

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 6, 2021Terms

Trial snapshot

StatusWITHDRAWN

PhasePHASE2

Enrollment—

Start dateJan 2020

Last updatedOct 6, 2021

Condition

Patent Ductus Arteriosus After Premature Birth

Locations shown

St. Boniface General Hospital Research Centre

Winnipeg, Manitoba

Health Sciences Centre

Winnipeg, Manitoba

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 6, 2021Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions